PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non–small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors-Reference-Cited by-同舟云学术

PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non–small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors

Published:2021-07 Issue:4 Volume:22 Page:351-360
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Ferrara Miriam Grazia,Martini Maurizio^ORCID,D’Argento Ettore,Forcella Chiara,Vita Emanuele,Di Noia Vincenzo,Sperduti Isabella,Bilotta Mirna,Ribelli Marta,Damiano Paola,Cannella Antonella,Stefani Alessio,Pilotto Sara,Carbone Carmine,Piro Geny,Milella Michele,Tortora Giampaolo,Bria Emilio

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference62 articles.

1. Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer;Schiller;N Engl J Med,2002

2. Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer;Tan;Lancet Oncol,2015

3. Rational biologically based treatment of EGFR-mutant non-small-cell lung cancer;Pao;Nat Rev Cancer,2010

4. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis;Zhang;Oncotarget,2016

5. Epidermal growth factor receptor (EGFR): a rising star in the era of precision medicine of lung cancer;Liu;Oncotarget,2017

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular mechanisms underlying the regulation of tumour suppressor genes in lung cancer;Biomedicine & Pharmacotherapy;2024-04

2. Advances in the role of microRNAs associated with the PI3K/AKT signaling pathway in lung cancer;Frontiers in Oncology;2023-12-19

3. Therapeutic Implications of PTEN in Non-Small Cell Lung Cancer;Pharmaceutics;2023-08-05

4. Drug resistance mechanisms and progress in the treatment of EGFR‑mutated lung adenocarcinoma (Review);Oncology Letters;2022-09-26

5. EGFR amplification is a putative resistance mechanism for NSCLC–LM patients with TKI therapy and is associated with poor outcome;Frontiers in Oncology;2022-08-01